

## Supporting Information

*Rec. Nat. Prod.* 18:1 (2024) 136-142

### A New Ascochlorin Glycoside from Brittlestar-derived Fungus *Acremonium* sp. and Its Biological Activities

Zhihong Luo<sup>1#</sup>, Kai Liu<sup>1#</sup>, Zhenzhou Tang<sup>1</sup>, Liang Peng<sup>2</sup>, Chenghai Gao<sup>1</sup>,  
Chenxi Xia<sup>1</sup>, Yonghong Liu<sup>1\*</sup> and Xianqiang Chen<sup>1\*</sup>

<sup>1</sup> Guangxi Key Laboratory of Marine Drugs, Institute of Marine Drugs, Guangxi University of Chinese Medicine, Nanning, Guangxi 530200, P. R. China


<sup>2</sup> Engineering Center of Jiangxi University for Fine Chemicals, School of Pharmacy, Jiangxi Science & Technology Normal University, Nanchang, Jiangxi 330013, P. R. China

Table of Contents	Page
<b>Figure S1:</b> HR-ESI-MS spectrum of acremonoside ( <b>1</b> )	3
<b>Figure S2:</b> <sup>1</sup> H NMR (500 MHz, CD <sub>3</sub> OD) spectrum of acremonoside ( <b>1</b> )	3
<b>Figure S3:</b> <sup>1</sup> H NMR (500 MHz, CD <sub>3</sub> OD) spectrum of acremonoside ( <b>1</b> ) (Enlarged)	4
<b>Figure S4:</b> <sup>13</sup> C NMR (125 MHz, CD <sub>3</sub> OD) spectrum of acremonoside ( <b>1</b> )	4
<b>Figure S5:</b> HSQC (500 MHz, CD <sub>3</sub> OD) spectrum of acremonoside ( <b>1</b> )	5
<b>Figure S6:</b> HSQC (500 MHz, CD <sub>3</sub> OD) spectrum of acremonoside ( <b>1</b> ) ( $\delta_{\text{H}}$ 0.4-2.7, $\delta_{\text{C}}$ 5-55)	5
<b>Figure S7:</b> HSQC (500 MHz, CD <sub>3</sub> OD) spectrum of acremonoside ( <b>1</b> ) ( $\delta_{\text{H}}$ 2.7-5.7, $\delta_{\text{C}}$ 55-126)	6
<b>Figure S8:</b> <sup>1</sup> H- <sup>1</sup> H COSY (500 MHz, CD <sub>3</sub> OD) spectrum of acremonoside ( <b>1</b> )	6
<b>Figure S9:</b> <sup>1</sup> H- <sup>1</sup> H COSY (500 MHz, CD <sub>3</sub> OD) spectrum of acremonoside ( <b>1</b> ) ( $\delta_{\text{H}}$ 0.5-5.5, $\delta_{\text{H}}$ 0.2-2.8)	7
<b>Figure S10:</b> <sup>1</sup> H- <sup>1</sup> H COSY (500 MHz, CD <sub>3</sub> OD) spectrum of acremonoside ( <b>1</b> ) ( $\delta_{\text{H}}$ 0.5-5.5, $\delta_{\text{H}}$ 2.8-5.8)	7
<b>Figure S11:</b> <sup>1</sup> H- <sup>1</sup> H COSY (500 MHz, CD <sub>3</sub> OD) spectrum of acremonoside ( <b>1</b> ) ( $\delta_{\text{H}}$ 2.9-4.0, $\delta_{\text{H}}$ 2.9-3.9)	8
<b>Figure S12:</b> HMBC (500 MHz, CD <sub>3</sub> OD) spectrum of acremonoside ( <b>1</b> )	8
<b>Figure S13:</b> HMBC (500 MHz, CD <sub>3</sub> OD) spectrum of acremonoside ( <b>1</b> ) ( $\delta_{\text{H}}$ 0.3-2.7, $\delta_{\text{C}}$ 5-58)	9
<b>Figure S14:</b> HMBC (500 MHz, CD <sub>3</sub> OD) spectrum of acremonoside ( <b>1</b> ) ( $\delta_{\text{H}}$ 0.3-2.7, $\delta_{\text{C}}$ 70-166)	9
<b>Figure S15:</b> HMBC (500 MHz, CD <sub>3</sub> OD) spectrum of acremonoside ( <b>1</b> ) ( $\delta_{\text{H}}$ 0.3-2.7, $\delta_{\text{C}}$ 155-220)	10
<b>Figure S16:</b> HMBC (500 MHz, CD <sub>3</sub> OD) spectrum of acremonoside ( <b>1</b> ) ( $\delta_{\text{H}}$ 2.8-5.8, $\delta_{\text{C}}$ 5-90)	10
<b>Figure S17:</b> HMBC (500 MHz, CD <sub>3</sub> OD) spectrum of acremonoside ( <b>1</b> ) ( $\delta_{\text{H}}$ 2.9-4.7, $\delta_{\text{C}}$ 95-167)	11
<b>Figure S18:</b> HMBC (500 MHz, CD <sub>3</sub> OD) spectrum of acremonoside ( <b>1</b> ) ( $\delta_{\text{H}}$ 4.75-6.0, $\delta_{\text{C}}$ 5-130)	11
<b>Figure S19:</b> HMBC (500 MHz, CD <sub>3</sub> OD) spectrum of acremonoside ( <b>1</b> ) ( $\delta_{\text{H}}$ 9.6-10.6, $\delta_{\text{C}}$ 110-200)	12
<b>Figure S20:</b> NOESY (500 MHz, CD <sub>3</sub> OD) spectrum of acremonoside ( <b>1</b> )	12
<b>Figure S21:</b> NOESY (500 MHz, CD <sub>3</sub> OD) spectrum of acremonoside ( <b>1</b> ) ( $\delta_{\text{H}}$ 0.5-5.0, $\delta_{\text{H}}$ 0.4-2.7)	13
<b>Figure S22:</b> NOESY (500 MHz, CD <sub>3</sub> OD) spectrum of acremonoside ( <b>1</b> ) ( $\delta_{\text{H}}$ 0.5-5.5, $\delta_{\text{H}}$ 2.9-4.6)	13
<b>Figure S23:</b> Linear correlation plots of experimental ( <b>1</b> ) versus calculated isomers ( <b>12S-1</b> and <b>12R-1</b> ) <sup>13</sup> C NMR chemical shifts	14
<b>Figure S24:</b> <sup>1</sup> H NMR (500 MHz, CDCl <sub>3</sub> ) spectrum of <b>2</b>	15
<b>Figure S25:</b> <sup>13</sup> C NMR (125 MHz, CDCl <sub>3</sub> ) spectrum of <b>2</b>	15
<b>Figure S26:</b> <sup>1</sup> H NMR (500 MHz, CDCl <sub>3</sub> ) spectrum of <b>3</b>	16
<b>Figure S27:</b> <sup>13</sup> C NMR (125 MHz, CDCl <sub>3</sub> ) spectrum of <b>3</b>	16
<b>Figure S28:</b> <sup>1</sup> H NMR (500 MHz, CDCl <sub>3</sub> ) spectrum of <b>4</b>	17
<b>Figure S29:</b> <sup>13</sup> C NMR (125 MHz, CDCl <sub>3</sub> ) spectrum of <b>4</b>	17
<b>Figure S30:</b> <sup>1</sup> H NMR (500 MHz, CDCl <sub>3</sub> ) spectrum of <b>5</b>	18


---

<b>Figure S31:</b> <sup>13</sup> C NMR (125 MHz, CDCl <sub>3</sub> ) spectrum of <b>5</b>	18
<b>Figure S32:</b> <sup>1</sup> H NMR (500 MHz, CDCl <sub>3</sub> ) spectrum of <b>6</b>	19
<b>Figure S33:</b> <sup>13</sup> C NMR (125 MHz, CDCl <sub>3</sub> ) spectrum of <b>6</b>	19
<b>Figure S34:</b> <sup>1</sup> H NMR (500 MHz, CDCl <sub>3</sub> ) spectrum of <b>7</b>	20
<b>Figure S35:</b> <sup>13</sup> C NMR (125 MHz, CDCl <sub>3</sub> ) spectrum of <b>7</b>	20
<b>Figure S36:</b> <sup>1</sup> H NMR (500 MHz, CDCl <sub>3</sub> ) spectrum of <b>8</b>	21
<b>Figure S37:</b> <sup>13</sup> C NMR (125 MHz, CDCl <sub>3</sub> ) spectrum of <b>8</b>	21
<b>Figure S38:</b> <sup>1</sup> H NMR (500 MHz, CDCl <sub>3</sub> ) spectrum of <b>9</b>	22
<b>Figure S39:</b> <sup>13</sup> C NMR (125 MHz, CDCl <sub>3</sub> ) spectrum of <b>9</b>	22
<b>Figure S40:</b> <sup>1</sup> H NMR (500 MHz, CD <sub>3</sub> OD) spectrum of <b>10</b>	23
<b>Figure S41:</b> <sup>13</sup> C NMR (125 MHz, CD <sub>3</sub> OD) spectrum of <b>10</b>	23
<b>Table S1:</b> Inhibitory effects of yeast α-glucosidase at the concentration of 10 mM	24
<b>Table S2:</b> Inhibitory activities of compounds <b>1-10</b> against tumor cells at the concentration of 40 μM	24
<b>Table S3:</b> Antibacterial activities of compounds <b>1-10</b>	25
<b>Figure S42:</b> Scifinder Search report for compound <b>1</b> (exact match)	26
<b>Figure S43:</b> Scifinder Search report for compound <b>1</b> (>95 % match)	27
<b>Table S4:</b> Comparison of NMR data between <b>1</b> and vertihemipterin A	28


---




**Figure S1:** HR-ESI-MS spectrum of acremonoside (**1**)




**Figure S2:**  $^1\text{H}$  NMR (500 MHz,  $\text{CD}_3\text{OD}$ ) spectrum of acremonoside (**1**)




**Figure S3:**  $^1\text{H}$  NMR (500 MHz,  $\text{CD}_3\text{OD}$ ) spectrum of acremonoside (**1**) (Enlarged)




**Figure S4:**  $^{13}\text{C}$  NMR (125 MHz,  $\text{CD}_3\text{OD}$ ) spectrum of acremonoside (**1**)




**Figure S5:** HSQC (500 MHz, CD<sub>3</sub>OD) spectrum of acremonoside (**1**)




**Figure S6:** HSQC (500 MHz, CD<sub>3</sub>OD) spectrum of acremonoside (**1**) ( $\delta_{\text{H}}$  0.4-2.7,  $\delta_{\text{C}}$  5-55)




**Figure S7:** HSQC (500 MHz, CD<sub>3</sub>OD) spectrum of acremonoside (**1**) ( $\delta_{\text{H}}$  2.7-5.7,  $\delta_{\text{C}}$  55-126)




**Figure S8:** <sup>1</sup>H-<sup>1</sup>H COSY (500 MHz, CD<sub>3</sub>OD) spectrum of acremonoside (**1**)




**Figure S9:** <sup>1</sup>H-<sup>1</sup>H COSY (500 MHz, CD<sub>3</sub>OD) spectrum of acremonoside (**1**) ( $\delta_{\text{H}}$  0.5-5.5,  $\delta_{\text{H}}$  0.2-2.8)




**Figure S10:** <sup>1</sup>H-<sup>1</sup>H COSY (500 MHz, CD<sub>3</sub>OD) spectrum of acremonoside (**1**) ( $\delta_{\text{H}}$  0.5-5.5,  $\delta_{\text{H}}$  2.8-5.8)




**Figure S11:**  $^1\text{H}$ - $^1\text{H}$  COSY (500 MHz,  $\text{CD}_3\text{OD}$ ) spectrum of acremonoside (**1**) ( $\delta_{\text{H}}$  2.9-4.0,  $\delta_{\text{H}}$  2.9-3.9)




**Figure S12:** HMBC (500 MHz,  $\text{CD}_3\text{OD}$ ) spectrum of acremonoside (**1**)




**Figure S13:** HMBC (500 MHz, CD<sub>3</sub>OD) spectrum of acremonoside (**1**) ( $\delta_{\text{H}}$  0.3-2.7,  $\delta_{\text{C}}$  5-58)




**Figure S14:** MBC (500 MHz, CD<sub>3</sub>OD) spectrum of acremonoside (**1**) ( $\delta_{\text{H}}$  0.3-2.7,  $\delta_{\text{C}}$  70-166)




**Figure S15:** HMBC (500 MHz, CD<sub>3</sub>OD) spectrum of acremonoside (**1**) ( $\delta_{\text{H}}$  0.3-2.7,  $\delta_{\text{C}}$  155-220)




**Figure S16:** HMBC (500 MHz, CD<sub>3</sub>OD) spectrum of acremonoside (**1**) ( $\delta_{\text{H}}$  2.8-5.8,  $\delta_{\text{C}}$  5-90)




**Figure S17:** HMBC (500 MHz, CD<sub>3</sub>OD) spectrum of acremonoside (**1**) ( $\delta_{\text{H}}$  2.9-4.7,  $\delta_{\text{C}}$  95-167)




**Figure S18:** HMBC (500 MHz, CD<sub>3</sub>OD) spectrum of acremonoside (**1**) ( $\delta_{\text{H}}$  4.75-6.0,  $\delta_{\text{C}}$  5-130)




**Figure S19:** HMBC (500 MHz, CD<sub>3</sub>OD) spectrum of acremonoside (**1**) ( $\delta_{\text{H}}$  9.6-10.6,  $\delta_{\text{C}}$  110-200)




**Figure S20:** NOESY (500 MHz, CD<sub>3</sub>OD) spectrum of acremonoside (**1**)



**Figure S21:** NOESY (500 MHz, CD<sub>3</sub>OD) spectrum of acremonoside (**1**) ( $\delta_{\text{H}}$  0.5-5.0,  $\delta_{\text{H}}$  0.4-2.7)




**Figure S22:** NOESY (500 MHz, CD<sub>3</sub>OD) spectrum of acremonoside (**1**) ( $\delta_{\text{H}}$  0.5-5.5,  $\delta_{\text{H}}$  2.9-4.6)




**Figure S23:** Linear correlation plots of experimental (**1**) versus calculated isomers (**12S-1** and **12R-1**) <sup>13</sup>C NMR chemical shifts


Note : Density functional theory methods were employed to facilitate <sup>13</sup>C chemical shift assignments of **1**. Conformational analyses were carried out by random searching with an energy cutoff of 7 kcal/mol using the Schrödinger MacroModel software package. The MMFF94 force field was employed. The conformers were optimized in the gas phase at the PCM (solvent = methanol) B3LYP-GD3BJ/6-31G(d) level using the Gaussian 16 program. NMR chemical shifts of **12R-1** and **12S-1** were calculated by the GIAO method at the mpw1pw91/6-31+G(d, p) level of theory in the methanol. The computational <sup>13</sup>C-NMR data were obtained by linear regression.




**Figure S24:**  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ) spectrum of **2**




**Figure S25:**  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ ) spectrum of **2**




**Figure S26:**  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ) spectrum of **3**




**Figure S27:**  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ ) spectrum of **3**




**Figure S28:**  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ) spectrum of **4**




**Figure S29:**  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ ) spectrum of **4**




**Figure S30:**  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ) spectrum of **5**




**Figure S31:**  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ ) spectrum of **5**




**Figure S32:**  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ) spectrum of **6**



**Figure S33:**  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ ) spectrum of **6**



**Figure S34:**  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ) spectrum of **7**



**Figure S35:**  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ ) spectrum of **7**




Figure S36:  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ) spectrum of **8**







Figure S37:  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ ) spectrum of **8**




**Figure S38:**  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ) spectrum of **9**



**Figure S39:**  $^{13}\text{C}$  NMR (125 MHz,  $\text{CDCl}_3$ ) spectrum of **9**



**Figure S40:**  $^1\text{H}$  NMR (500 MHz,  $\text{CD}_3\text{OD}$ ) spectrum of **10**



**Figure S41:**  $^{13}\text{C}$  NMR (125 MHz,  $\text{CD}_3\text{OD}$ ) spectrum of **10**

**Table S1 :** Inhibitory effects of yeast  $\alpha$ -glucosidase at the concentration of 10 mM

Compounds	Inhibitory rate (%)
<b>1</b>	62.7
<b>2</b>	6.1
<b>3</b>	26.6
<b>7</b>	59.9
<b>8</b>	54.6
<b>10</b>	56.1
<b>Acarbose<sup>a</sup></b>	95.5

<sup>a</sup> positive control, the inhibitory rate was determined at the concentration of 4  $\mu$ M.

**Table S2 :** Inhibitory activities of compounds **1-10** against tumor cells at the concentration of 40  $\mu$ M

Compounds	Inhibitory rate (%)		
	DLD1	SW1990	PANC1
<b>1</b>	-	-	-
<b>2</b>	54.8	59.1	37.9
<b>3</b>	16.2	66.1	3.3
<b>4</b>	6.0	57.7	26.6
<b>5</b>	76.7	67.6	60.5
<b>6</b>	72.2	67.7	64.3
<b>7</b>	13.3	66.3	35.8
<b>8</b>	66.2	65.5	51.1
<b>9</b>	69.2	67.9	49.3
<b>10</b>	19.4	72.1	35.2

- inactive. DLD1 human colorectal carcinoma cells DLD1. SW1990 pancreatic cancer cell line SW1990. PANC1 pancreatic cancer cell line PANC1.

**Table S3** : Antibacterial activities of compounds **1-10**

compounds	MIC ( $\mu\text{g/mL}$ )					
	<i>Actinomyces viscosus</i>	<i>Staphylococcus epidermidis</i>	<i>Bacillus subtilis</i>	MASR	<i>Staphylococcus aureus</i>	<i>Micrococcus luteus</i>
<b>1</b>	-	-	-	-	-	-
<b>2</b>	31.25	15.625	62.500	-	125.000	-
<b>3</b>	7.81	3.90	3.90u0	62.500	7.810	3.90
<b>4</b>	7.81	7.81	7.810	7.810	15.6250	3.90
<b>5</b>	1.95	1.95	3.900	15.6250	7.810	7.81
<b>6</b>	1.95	3.90	7.810	-	15.6250	62.5
<b>7</b>	62.5	31.25	31.250	62.50	62.50	31.25
<b>8</b>	1.95	1.95	1.950	31.250	3.900	7.81
<b>9</b>	7.81	7.81	7.810	31.250	7.81	15.625
<b>10</b>	3.90	3.90	3.900	15.6250	-	1.95
Ciprofloxacin <sup>a</sup>	3.125	0.39	0.39	0.78	6.25	3.125

- no inhibitory activity at the concentration of 125  $\mu\text{g/mL}$ . MRSA Methicillin-resistant *Staphylococcus aureus*. <sup>a</sup> positive control

## Initiating Search

January 2, 2024, 4:09PM

## Substances:


Filtered By:

Similarity:

Number of Components:

95-98, 80-84

1

Structure Match: **Similarity**





## Search Tasks

Task	Search Type	View
Exported: Returned Substance Results + Filters (16)	 Substances	<a href="#">View Results</a>

Copyright © 2024 American Chemical Society (ACS). All Rights Reserved.

Internal use only. Redistribution is subject to the terms of your SciFinder® License Agreement and CAS information Use Policies.

**Figure S43:** Scifinder Search report for compound **1** (exact match)

<p>1 Similarity Score: 99</p> <p>765956-86-3</p>  <p>Absolute stereochemistry shown Double bond geometry shown</p> <p><b>C<sub>30</sub>H<sub>43</sub>O<sub>10</sub></b> 3-Chloro-4,6-dihydroxy-2-methyl-5-[(2<i>E</i>,4<i>R</i>)-3-methyl-4-[(4-<i>O</i>-methyl-β-D-glucopyranosyl)oxy]-5-[(1<i>S</i>,2<i>R</i>,6<i>R</i>)-1,2,6-trimethyl-3-oxocyclohexyl]-2-penten-1-yl]benzaldehyde</p> <p>References: 2, Reactions: 0, Suppliers: 0</p>	<p>2 Similarity Score: 83</p> <p>165187-17-7</p>  <p>Absolute stereochemistry shown, Rotation (+) Double bond geometry shown</p> <p><b>C<sub>28</sub>H<sub>39</sub>O<sub>6</sub></b> (1<i>R</i>,2<i>E</i>)-4-(3-Chloro-5-formyl-2,6-dihydroxy-4-methylphenyl)-2-methyl-1-[[[(1<i>S</i>,2<i>R</i>,6<i>R</i>)-1,2,6-trimethyl-3-oxocyclohexyl]methyl]-2-buten-1-yl 3-methylbutanoate</p> <p>References: 4, Reaction: 1, Supplier: 1</p>	<p>3 Similarity Score: 83</p> <p>2111912-99-1</p>  <p><b>C<sub>23</sub>H<sub>31</sub>O<sub>6</sub></b> 3-Chloro-4,6-dihydroxy-5-[4-hydroxy-3-(hydroxymethyl)-5-(1,2,6-trimethyl-3-oxocyclohexyl)-2-penten-1-yl]-2-methylbenzaldehyde</p> <p>References: 0, Reactions: 0, Supplier: 1</p>
<p>4 Similarity Score: 83</p> <p>1214976-02-9</p>  <p>Relative stereochemistry shown Double bond geometry unknown</p> <p><b>C<sub>27</sub>H<sub>37</sub>O<sub>6</sub></b> <i>rel</i>-(1<i>S</i>)-4-(3-Chloro-5-formyl-2,6-dihydroxy-4-methylphenyl)-2-methyl-1-[[[(1<i>R</i>,2<i>S</i>,6<i>S</i>)-1,2,6-trimethyl-3-oxocyclohexyl]methyl]-2-buten-1-yl 2-methylpropanoate</p> <p>References: 0, Reactions: 0, Suppliers: 0</p>		

Copyright © 2024 American Chemical Society (ACS). All Rights Reserved.

Internal use only. Redistribution is subject to the terms of your SciFinder<sup>®</sup> License Agreement and CAS information Use Policies.**Figure S44:** Scifinder Search report for compound 1 (>95 % match)

**Table S4:** Comparison of NMR data between **1** and vertihemipterin A

Position	1 in CD <sub>3</sub> OD		Vertihemipterin A in CDCl <sub>3</sub>	
	$\delta_C$ (type)	$\delta_H$ (multiplicity, <i>J</i> in Hz)	$\delta_C$ (type)	$\delta_H$ (multiplicity, <i>J</i> in Hz)
1	114.3 (C)		113.5 (C)	
2	161.5 (C)		162.0 (C)	
3	113.6 (C)		113.3 (C)	
4	159.3 (C)		156.2 (C)	
5	112.4 (C)		113.3 (C)	
6	138.3 (C)		138.3 (C)	
7	13.2 (CH <sub>3</sub> )	2.55 (s)	14.5 (CH <sub>3</sub> )	2.60 (s)
8	193.2 (C)		193.3 (C)	
9	21.0 (CH <sub>2</sub> )	3.40 (dd, 13.5, 8)	21.5 (CH <sub>2</sub> )	3.40 (m) ; 3.37 (m)
10	125.0 (CH)	5.57 (t, 7.5)	124.4 (CH)	5.41 (t, 7.0)
11	137.2 (C)		138.3 (C)	
12	83.0 (CH)	4.16 (t, 6.0)	85.1 (CH)	6.42 (dd, 6.1, 4.2)
13	39.3 (CH <sub>2</sub> )	1.77 (dd, 15.5, 6.0); 1.50 (dd, 15.5, 5.0)	40.6 (CH <sub>2</sub> )	1.85 (dd, 15.6, 6.6) ; 1.4 (dd, 15.6, 3.9)
14	43.7 (C)		44.0 (C)	
15	36.0 (CH)	2.21 (m)	36.5 (CH)	2.22 (m)
16	30.9 (CH <sub>2</sub> )	1.79 (m); 1.50 (dq, 12.5, 5.0)	31.1 (CH <sub>2</sub> )	1.80 (m); 1.57 (dq, 13.0, 5.4)
17	41.0 (CH <sub>2</sub> )	2.18 (m); 2.12 (m)	41.3 (CH <sub>2</sub> )	2.28 (ddd, 13.5, 5.4, 2.4); 2.21 (m)
18	215.4 (C)		213.8 (C)	
19	50.1 (CH)	2.59 (q, 7.0)	50.4 (CH)	2.53 (q, 6.7)
20	14.6 (CH <sub>3</sub> )	0.51 (s)	15.6 (CH <sub>3</sub> )	0.57 (s)
21	14.7 (CH <sub>3</sub> )	0.97 (d, 6.5)	15.8 (CH <sub>3</sub> )	0.98 (d, 6.7)
22	7.2 (CH <sub>3</sub> )	0.69 (d, 7.0)	8.1 (CH <sub>3</sub> )	0.77 (d, 6.7)
23	10.5 (CH <sub>3</sub> )	1.83 (s)	11.5 (CH <sub>3</sub> )	1.82 (s)
1'	99.4 (CH)	4.45 (brs)	101.9 (CH)	4.22 (d, 7.9)
2'	71.4 (CH)	3.82 (d 3.0)	74.1 (CH)	3.38 (m)
3'	74.2 (CH)	3.37 (dd, 9.5, 3.0)	76.7 (CH)	3.56 (t, 8.8)
4'	66.7 (CH)	3.59 (t, 9.5)	79.9 (CH)	3.08 (dd, 9.5, 8.7)
5'	76.6 (CH)	2.97 (ddd, 9.5, 5.0, 3.0)	75.2 (CH)	3.14 (ddd, 9.5, 5.7, 2.8)
6'	61.1 (CH <sub>2</sub> )	3.69 (dd, 11.5, 3.0); 3.65 (dd, 11.5, 5.0)	62.5 (CH <sub>2</sub> )	3.79 (dd, 11.6, 2.7) 3.64 (dd, 11.6, 5.7)
4'-OCH <sub>3</sub>			60.7 (CH <sub>3</sub> )	3.55 (s)